Jeffrey Sharpe holds 1,500,000 Conexeu Sciences common shares, equal to 5.2% of the outstanding stock, after exercising 500,000 performance warrants on September 14, 2026. The activist position gives Sharpe sole voting and dispositive power, while another 500,000 unvested warrants remain excluded from his ownership calculation.

Key Highlights

  • The transaction produced aggregate proceeds of $500.00 for Conexeu Sciences and was funded with Sharpe’s personal money.
  • Sharpe has sole voting and dispositive power over the common stock covered by his position.
  • Sharpe beneficially owns 1,500,000 shares of Conexeu Sciences common stock.

Conexeu Sciences Inc. (NASDAQ: CNXU) director Jeffrey Sharpe holds an activist stake equal to 5.2% of the company’s outstanding common stock. His position consists of 1,500,000 shares and reflects ownership reported as of September 14, 2026. Sharpe acquired the securities through compensation arrangements and says he currently holds them for Investment purposes. The updated ownership followed Sharpe’s exercise of vested performance warrants.

Sharpe’s Ownership Position

Conexeu Sciences had 28,706,698 shares of common stock outstanding as of September 14, 2026, which forms the basis for the 5.2% ownership calculation. Sharpe directly holds the reported common shares and has sole voting power and sole dispositive power over them. A further 500,000 performance warrants are excluded from the ownership figure.

Three Warrant Milestones Completed

The transaction produced aggregate proceeds of $500.00 for Conexeu Sciences, funded with Sharpe’s personal money. That milestone occurred on June 18, 2026. Sharpe had previously exercised another 500,000 warrants on May 22, 2026, after they vested on May 21, 2026, the date Conexeu Sciences listed its shares on Nasdaq. An earlier milestone tied to completion and receipt of results from a three-month collagen study was achieved on July 8, 2025. Sharpe exercised the resulting 500,000 warrants on December 23, 2025, acquiring the shares for aggregate consideration of $500.00. The original consulting arrangement granted Sharpe 2,000,000 performance warrants, divided equally across four milestones. The remaining milestone concerns submission of the 510(k) application.

Sharpe May Change His Holdings

Sharpe states that he may acquire or dispose of Conexeu Sciences securities depending on market conditions and other factors. Potential transactions may include open-market purchases or sales and privately negotiated transactions. He may also exchange common shares for other Assets or sell shares to increase his cash position. Sharpe reserves the ability to formulate other plans, make proposals and change those plans or proposals. The securities were acquired in connection with compensation arrangements, while the current stated purpose is investment. Sharpe may receive stock Options or other equity-based compensation from Conexeu Sciences from time to time. The unvested warrants remain outside the current ownership calculation until their stated vesting condition is met.